The President of the Swiss National Bank said the strong Swiss franc was one factor influencing the SNB's decision to cut its interest rate to zero. Martin Schlegel also said that Switzerland was ready to intervene in the FX market if necessary. Schlegel spoke with Bloomberg’s Bastian Benrath in Zurich. 00:00 - SNB interest rate decision 00:58 - Swiss franc, currency 01:52 - Oil prices, inflation, effect on economy, intervention in FX market, monetary policy 04:55 - Tariffs, trade, impact on Swiss economy 0 ...

Speculation rampant the last couple of days about what the US are going to do, whether they actually do want to get involved militarily. Big story from our Bloomberg colleagues overnight. What do we know.Very much so. So the US is preparing for potential strikes. So I think we've got to the point now where whatever the US might do, those plans are in place and they can go instantly if Donald Trump decides that that's what he wants to do.We're still very unclear at the moment exactly what those plans are, wh ...

Core Insights - The healthcare landscape is increasingly influenced by technology, with Intuitive Surgical (ISRG) and Boston Scientific (BSX) recognized for their innovation and long-term potential in minimally invasive procedures [1][2] - Investors are considering these companies as attractive long-term investments due to growing demand for advanced surgical solutions and an aging global population [2] Price Performance - Intuitive Surgical has experienced a year-to-date decline of 1.9%, while Boston Scientific has seen a gain of 13.9%, attributed to BSX's diversified business and strong U.S. demand [4] - ISRG is characterized as a high-growth, high-premium investment in robotic-assisted surgery, while BSX offers broader exposure to medical device innovation with more moderate valuation [3] Market Position & Core Offerings - Intuitive Surgical leads the surgical robotics market with its da Vinci system, achieving a 17% year-over-year increase in procedures [5] - Boston Scientific operates across various interventional medical devices, with notable success in cardiovascular sales, which increased by 26% in the first quarter of 2025 [5] Growth & Performance - ISRG reported a 19% revenue growth to $2.25 billion and a 22% increase in adjusted net income to $767.5 million in Q1 2025 [6][8] - BSX also posted strong earnings with adjusted EPS of $0.75 and sales of $4.66 billion, driven by its cardiovascular and medical-surgical divisions [9] Estimates Comparison - The Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS indicates a year-over-year improvement of 15.6% and 6.8%, respectively [10] - For BSX, the estimates imply a year-over-year improvement of 16.4% in sales and 15.9% in EPS for 2025 [12] Cash & Cash Flow - Intuitive Surgical has a strong balance sheet with $4.51 billion in cash and no debt, generating free cash flow of approximately $465 million [15] - Boston Scientific reported $725 million in cash and $11.31 billion in total debt, but still generated $541 million in operating cash flow [16] Investment Considerations - ISRG is seen as a superior choice for investors seeking explosive growth in surgical robotics, while BSX may appeal to those preferring balanced exposure across med-tech segments [18] - Both companies currently hold a Zacks Rank 3 (Hold), but BSX has a better Zacks Style Score of 'C' compared to ISRG's 'D', indicating better growth potential for BSX [20]

Core Insights - The Global Longevity Summit is set to take place from October 28–30, 2025, at the Genolier Innovation Hub in Geneva, Switzerland, focusing on advancements in aging science and human performance [3][5] - Dr. Steve Horvath, a biogerontologist and epigenetic researcher, will be the keynote speaker and will receive the 2025 Global Longevity Award for his work on the epigenetic clock [2][3] - The event will feature 300 global leaders from healthcare, science, business, and capital, emphasizing the theme "Mastering the Aging Clock: The Science of Longevity" [3][4] Event Details - The Summit will include discussions on epigenetics, regenerative medicine, AI-powered health optimization, and precision intervention strategies [3] - New members have been appointed to the Scientific and Professional Advisory Board, enhancing the event's multidisciplinary approach [4] - Early registration is encouraged due to rising demand, with ticket prices set to increase on July 1 [5] Participation Information - The Global Longevity Summit is an invitation-only event, requiring participant approval for qualified professionals and executives in the longevity ecosystem [6][7] - Interested participants can apply for access through the official website [6]

health secretary naming some vaccine critics to replace that CDC panel we've been telling you about. Remember, he just ousted a committee of 17 independent experts on vaccines earlier this week. His new eight picks include several well-known vaccine skeptics and others who are critical of pandemic interventions like lockdowns. ...

Glaukos (GKOS) FY Conference June 03, 2025 01:40 PM ET Speaker0 How's it going, everyone? I'm gonna step in. My name is Macaulay Cobain. I work under Margaret Kayser covering med tech. We're gonna have Glaukos present for us. We have management with us today. You can go to WilliamBlair.com for a full list of our disclosures, and we'll, we'll have Alex kick it off here. Speaker1 Alright. Thank you all for coming and joining us, this afternoon and to talk a little bit about Glaukos. My pleasure to, speak to y ...

Summary of Thai Life Sciences and Beckley Cytec Conference Call Company and Industry Overview - The conference call involved **Thai Life Sciences** and **Beckley Cytec**, focusing on their business combination aimed at developing psychedelic treatments for mental health conditions [4][10]. Key Points and Arguments 1. **Business Combination Announcement**: The merger between Assata Life Sciences and Beckley Cytec is expected to create significant synergies and unlock value for patients and shareholders [4][10]. 2. **Psychedelic Research Background**: Beckley Cytec has a history of scientific research into psychedelics, aiming to develop these compounds into approved pharmaceutical medicines for mental health conditions [5][6]. 3. **Pipeline Focus**: The combined company will have a focused pipeline of differentiated psychedelic products, including BPL-three and BPL-one, targeting treatment-resistant depression and social anxiety disorder [8][13]. 4. **Upcoming Milestones**: The company anticipates several important milestones, including the results of the BPL-three Phase 2b trial, expected in the middle of the year [14][15]. 5. **Market Opportunity**: The psychedelic compounds are positioned within the interventional psychiatry paradigm, targeting treatment-resistant conditions. The success of SPRAVATO, which achieved $930 million in sales, highlights the market potential for these new treatments [16][17]. 6. **Efficacy and Administration**: The compounds BPL-three and BPL-one are designed for shorter administration times compared to existing treatments, potentially improving patient compliance and outcomes [20][25]. 7. **Intellectual Property (IP) Strategy**: The company has a strong IP position with multiple patents granted in the U.S. and Europe, ensuring protection for their proprietary formulations [50][51]. 8. **Regulatory Interactions**: The company has had positive interactions with the FDA regarding their development programs, indicating a clear path forward for Phase III trials [66][68]. Additional Important Content 1. **Safety Profile**: The Phase 1 and 2a studies indicated that BPL-three was well tolerated, with a high percentage of participants willing to take the treatment again [30][44]. 2. **Differentiation from Competitors**: The company believes that their intranasal delivery method and single administration model provide significant advantages over competitors like GH Research, which uses a more complex inhalation device [96][97]. 3. **Future Directions**: The company is open to exploring additional indications for their compounds beyond depression, including anxiety disorders and PTSD, depending on the results of ongoing studies [102][103]. 4. **Spin-off Plans**: The LE-one hundred one compound will be spun out into a separate entity, allowing the combined company to focus on its core assets while still retaining a stake in the new venture [104][105]. This summary encapsulates the key discussions and insights from the conference call, highlighting the strategic direction and potential of the combined company in the psychedelic treatment landscape.

Core Insights - The FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM), marking a significant step in the treatment landscape for this condition [1][2][3] Company Insights - Johnson & Johnson aims to transform oncology care by advocating for early intervention in high-risk smoldering multiple myeloma, potentially delaying or preventing progression to active multiple myeloma [4][6] - The company emphasizes its commitment to evolving treatment paradigms for multiple myeloma, aligning with its vision for a future where early diagnosis and treatment are standard [4][5] Industry Insights - Currently, there are no approved treatments specifically for HR-SMM, with an estimated 35,000 new multiple myeloma cases expected in the U.S. in 2024, of which approximately 15% are classified as smoldering [3][7] - The standard of care for smoldering multiple myeloma is active monitoring, which may delay therapeutic intervention until significant disease progression occurs [3][8] - The AQUILA study, a Phase 3 trial, demonstrated that early intervention with DARZALEX FASPRO® could reduce the risk of progression or death in patients with HR-SMM [4][6]

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...